Evidence map›Paper›PMID 23649632›Full record

ArticleThe Journal of biological chemistry2013

Smad2 is essential for maintenance of the human and mouse primed pluripotent stem cell state.

Masayo Sakaki-Yumoto, Jianming Liu, Miguel Ramalho-Santos, Nobuaki Yoshida, Rik Derynck

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. ModelingJournal of the American Heart Association · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The Role of SMAD2/3 in Human Embryonic Stem Cells.Frontiers in cell and developmental biology · 2020
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Masayo Sakaki-YumotoEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Program in Cell Biology, University of California, San Francisco, California 94143, USA.
Jianming Liu
Miguel Ramalho-Santos
Nobuaki Yoshida
Rik Derynck
Biologie du Développement et Cellules SouchesSystems Biology Institute · JPTokyo University of Science · JPUniversity of California, San Francisco · US

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2003 to 2019
$21.8M
NHLBI NIH HHS R21 HL0923494NIDDK NIH HHS P30 DK063720
6 · The paper itself

Abstract

Human embryonic stem cells and mouse epiblast stem cells represent a primed pluripotent stem cell state that requires TGF-β/activin signaling. TGF-β and/or activin are commonly thought to regulate transcription through both Smad2 and Smad3. However, the different contributions of these two Smads to primed pluripotency and the downstream events that they may regulate remain poorly understood. We addressed the individual roles of Smad2 and Smad3 in the maintenance of primed pluripotency. We found that Smad2, but not Smad3, is required to maintain the undifferentiated pluripotent state. We defined a Smad2 regulatory circuit in human embryonic stem cells and mouse epiblast stem cells, in which Smad2 acts through binding to regulatory promoter sequences to activate Nanog expression while in parallel repressing autocrine bone morphogenetic protein signaling. Increased autocrine bone morphogenetic protein signaling caused by Smad2 down-regulation leads to cell differentiation toward the trophectoderm, mesoderm, and germ cell lineages. Additionally, induction of Cdx2 expression, as a result of decreased Smad2 expression, leads to repression of Oct4 expression, which, together with the decreased Nanog expression, accelerates the loss of pluripotency. These findings reveal that Smad2 is a unique integrator of transcription and signaling events and is essential for the maintenance of the mouse and human primed pluripotent stem cell state.

Indexed as

AnimalsBone Morphogenetic ProteinsCDX2 Transcription FactorCell DifferentiationCells, CulturedEmbryonic Stem CellsGerm LayersHomeodomain ProteinsHumansImmunoblottingMiceMice, 129 StrainMicroscopy, FluorescenceNanog Homeobox ProteinOctamer Transcription Factor-3Pluripotent Stem CellsBone Morphogenetic ProteinsCDX2 protein, humanCDX2 Transcription FactorHomeodomain ProteinsNanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanSmad2 ProteinSmad3 ProteinTransforming Growth Factor betaBone Morphogenetic Protein (BMP)Cell DifferentiationNanogPluripotencySmad Transcription FactorStem CellsTransforming Growth Factor β (TGFβ)

Identifiers

PMID23649632
PMCPMC3689995
OpenAlexW2042047157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.